[go: up one dir, main page]

MXPA01008870A - Metodo para validar y/o invalidar blancos y rutas. - Google Patents

Metodo para validar y/o invalidar blancos y rutas.

Info

Publication number
MXPA01008870A
MXPA01008870A MXPA01008870A MXPA01008870A MXPA01008870A MX PA01008870 A MXPA01008870 A MX PA01008870A MX PA01008870 A MXPA01008870 A MX PA01008870A MX PA01008870 A MXPA01008870 A MX PA01008870A MX PA01008870 A MXPA01008870 A MX PA01008870A
Authority
MX
Mexico
Prior art keywords
target
mrna
oligos
disease
condition
Prior art date
Application number
MXPA01008870A
Other languages
English (en)
Spanish (es)
Inventor
L Hill Jeffrey
Original Assignee
Epigenesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Inc filed Critical Epigenesis Pharmaceuticals Inc
Publication of MXPA01008870A publication Critical patent/MXPA01008870A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MXPA01008870A 1999-03-05 2000-03-02 Metodo para validar y/o invalidar blancos y rutas. MXPA01008870A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12295099P 1999-03-05 1999-03-05
PCT/US2000/005643 WO2000051621A1 (fr) 1999-03-05 2000-03-02 Procede de validation/d'invalidation de cibles et des voies

Publications (1)

Publication Number Publication Date
MXPA01008870A true MXPA01008870A (es) 2004-08-12

Family

ID=22405857

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008870A MXPA01008870A (es) 1999-03-05 2000-03-02 Metodo para validar y/o invalidar blancos y rutas.

Country Status (10)

Country Link
EP (1) EP1165093A4 (fr)
JP (1) JP2002537792A (fr)
KR (1) KR20020068262A (fr)
CN (1) CN1348376A (fr)
AU (1) AU3512300A (fr)
BR (1) BR0009247A (fr)
CA (1) CA2366055A1 (fr)
IL (1) IL145034A0 (fr)
MX (1) MXPA01008870A (fr)
WO (1) WO2000051621A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001238342A1 (en) * 2000-02-17 2001-08-27 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
CN101384721A (zh) 2006-02-13 2009-03-11 孟山都技术有限公司 选择和稳定dsRNA构建体
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
EP2182980A4 (fr) 2007-07-27 2012-04-18 Armagen Technologies Inc Procédés et compositions destinés à augmenter une activité a-iduronidase dans le snc
EP2408474B1 (fr) 2009-03-18 2019-06-26 Armagen, Inc. Compositions et procédés pour le transport de protéines de fusion igg-récepteur leurre à travers la barrière hémato-encéphalique
SI2485761T1 (sl) 2009-10-09 2019-05-31 Armagen, Inc. Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
CN102169121B (zh) * 2010-02-25 2013-12-04 北京诺赛基因组研究中心有限公司 人类激酶sbk1的新应用
EP2785378B1 (fr) 2011-12-02 2020-05-13 Armagen, Inc. Méthodes et compositions pour augmenter l'activité arylsulfatase a dans le système nerveux central
WO2015009961A1 (fr) * 2013-07-19 2015-01-22 Armagen Technologies, Inc. Compositions et procédés associés à des structures qui traversent la barrière hémato-encéphalique
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3093022B1 (fr) 2015-05-15 2019-08-07 Sterna Biologicals GmbH & Co. KG Inhibiteurs gata-3 destinés à être utilisés dans le traitement de l'asthme à base de th2
CN114480406B (zh) * 2021-09-16 2024-01-30 广东翠点生物科技有限公司 一种il-1信号通路响应元件及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
AU2725600A (en) * 1999-01-13 2000-08-01 Du Pont Pharmaceuticals Company Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in (in vivo) cnsstudies of gene function

Also Published As

Publication number Publication date
WO2000051621A1 (fr) 2000-09-08
CA2366055A1 (fr) 2000-09-08
JP2002537792A (ja) 2002-11-12
AU3512300A (en) 2000-09-21
KR20020068262A (ko) 2002-08-27
EP1165093A4 (fr) 2002-07-24
IL145034A0 (en) 2002-06-30
CN1348376A (zh) 2002-05-08
BR0009247A (pt) 2001-11-20
EP1165093A1 (fr) 2002-01-02

Similar Documents

Publication Publication Date Title
MXPA01008870A (es) Metodo para validar y/o invalidar blancos y rutas.
Fujiki et al. Cancer inhibition by green tea
Papa et al. Insulin receptors in breast cancer: biological and clinical role
Han et al. Distinct mechanisms of TGF-β1–mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis
Merritt et al. Apoptosis in small intestinal epithelia from p53-null mice: evidence for a delayed, p53-indepdendent G2/M-associated cell death after γ-irradiation
Benzil et al. Expression pattern of α-protein kinase C in human astrocytomas indicates a role in malignant progression
Butler et al. Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression
Morris et al. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines
Zhang et al. Apoptosis of hippocampal neurons after amygdala kindled seizures
Maric et al. Bone morphogenetic protein‐7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats
US20020102245A1 (en) 14-3-3sigma arrests the cell cycle
CA2501719C (fr) Remede ou agent preventif contre une maladie des reins et procede de diagnostic d'une maladie des reins
Saadane et al. Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice
Biswal et al. Management of intracranial metastases of differentiated carcinoma of thyroid
Devi et al. Inhibition of human chorionic gonadotropin β‐subunit modulates the mitogenic effect of c‐myc in human prostate cancer cells
Farooq et al. Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest
Tian et al. External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor‐targeted radionuclide‐PNA‐peptide chimeras
Masson et al. Differential regenerative response and expression of growth factors following hepatectomy of variable extent in rats
Luzzi et al. Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI)
KR101911659B1 (ko) 암 줄기세포를 포함하거나 또는 그것에서 유래하는 암의 치료, 예방 및 진단을 위한 방법 및 조성물
Sturgeon et al. Physical activity induced protection against breast cancer risk associated with delayed parity
Moen et al. Different genetic susceptibility to aberrant crypts and colon adenomas in mice
CN108004310B (zh) 肾素(原)受体(p)rr基因及其抑制剂的应用
CN105648076B (zh) Nudt11基因及其表达产物作为子宫肌瘤的诊治靶标
Little et al. Enhanced expression of insulin-like growth factor II is not a necessary event in Wilms' tumour progression